Many patients tend to favour pharmacological approaches over surgery due to their non-invasive nature, avoidance of permanent physical changes, and potentially reduced risk of immediate postoperative complications.22,23 Reducing testosterone levels plays a vital role in managing prostate cancer by slowing disease progression and potentially enhancing patient survival.24,25 A study suggests that LHRH agonist therapy is more effective in achieving testosterone reduction to the target castrate range.16,20 LHRH agonists ensure sustained testosterone suppression over time. This evidence concerns the gene GNRH1 and prostate cancer.